Innovations in Finance & Technology:
The Power of Public-Private Partnerships

Dr Raman Rao
CEO, Hilleman Laboratories

21 October 2022
DCVMN AGM, Pune
Of all the products in the world you don’t want to use market-based prioritization, it has got to be vaccines.

– Bill Gates
Financial Times, March 2021
How do we de-risk vaccine development?

The process of developing, testing and recommending a vaccine candidate which has demonstrated potential effects is inevitably challenged by the 'valleys of death'. Overcoming these death valleys require multipronged approaches.
2 years later...

In 2007, the first Advance Market Commitment (AMC) for a vaccine was set up to stimulate R&D for a pneumococcal vaccine; a total of US$1.5 billion was committed.
Global health focused PPPs have used AMCs to create markets for previously unincentivised vaccines for neglected diseases, to incentivise biotech and pharmaceutical companies to invest in R&D for new vaccines for unmet needs.
Financing Joint Ventures with a Public Health Mission

Hilleman Laboratories is an equal joint-venture partnership formed between Merck Sharp & Dohme Corp. (MSD), a global research-driven pharmaceutical company and Wellcome Trust, a global charitable foundation dedicated to supporting science and solving urgent health challenges.

VISION
Developing Vaccines for Global Health

MISSION
Hilleman Laboratories is committed to developing high impact, affordable vaccines for people in developing countries in an innovative and sustainable manner.

HillChol® enters Phase III in August 2022

Source: Stock image
Financing National Infrastructure for Vaccine Security

“... manufacturing facilities ready to go that are there in case of an outbreak, you will need to make sure there’s financing for that.. This makes public health sense, as a partnership between government and the public sector”

– Seth Berkley, CEO of Gavi; adapted from Financial Times, March 2021
A caveat for supporting Vaccine Infrastructure

A conducive environment for viability and survivability of local/domestic vaccine producers is crucial.

This not only includes ensuring a steady demand or uptake of vaccines, but also support from government administration and regulatory bodies.
How do we make vaccines more affordable and more accessible?

- **Innovative Platform Technologies**
  - For higher yield
  - For improved delivery
  - For extended shelf-life and improved stability

- **Strategic Manufacturing Technologies**
  - Continuous manufacturing
  - PAT and real-time lot release
  - Reconfigurable, modular manufacturing
  - Single-use systems

Source: Stock image